Juan García Valero

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma

Anna Esteve‐Arenys, Juan García Valero, Aránzazu Chamorro-Jorganes et al. · Oncogene · 2018 · 81 citations

Medicine, Oncology, Pharmacology +14

The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma

Juan García Valero, Alba Matas‐Céspedes, Fabián Arenas et al. · Leukemia · 2021 · 66 citations · Full text

Life Sciences, Immunology, Oncology +17

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

Neus Giménez, Alejandra Martínez‐Trillos, Arnau Montraveta et al. · Haematologica · 2018 · 62 citations · Full text

Medicine, Molecular Genetics, Oncology +15

Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells

Juan García Valero, Lucie Sancey, Jérôme Kucharczak et al. · Journal of Cell Science · 2011 · 56 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Anna Vidal‐Crespo, Alba Matas‐Céspedes, Vanina Rodríguez et al. · Haematologica · 2019 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17